Orianne Dumas1, Jonathan M Mansbach2, Tuomas Jartti3, Kohei Hasegawa4, Ashley F Sullivan5, Pedro A Piedra6, Carlos A Camargo4. 1. Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA Harvard Medical School, Boston, Massachusetts, USA Inserm, VIMA, Aging and Chronic Diseases. Epidemiological and Public Health Approaches, U1168, Villejuif, France UMR-S 1168, University Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France. 2. Harvard Medical School, Boston, Massachusetts, USA Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA. 3. Department of Pediatrics, Turku University Hospital, Turku, Finland. 4. Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA Harvard Medical School, Boston, Massachusetts, USA. 5. Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 6. Departments of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Abstract
OBJECTIVE: Although bronchiolitis is generally considered a single disease, recent studies suggest heterogeneity. We aimed to identify severe bronchiolitis profiles using a clustering approach. METHODS: We analysed data from two prospective, multicentre cohorts of children younger than 2 years hospitalised with bronchiolitis, one in the USA (2007-2010 winter seasons, n=2207) and one in Finland (2008-2010 winter seasons, n=408). Severe bronchiolitis profiles were determined by latent class analysis, classifying children based on clinical factors and viral aetiology. RESULTS: In the US study, four profiles were identified. Profile A (12%) was characterised by history of wheezing and eczema, wheezing at the emergency department (ED) presentation and rhinovirus infection. Profile B (36%) included children with wheezing at the ED presentation, but, in contrast to profile A, most did not have history of wheezing or eczema; this profile had the largest probability of respiratory syncytial virus infection. Profile C (34%) was the most severely ill group, with longer hospital stay and moderate-to-severe retractions. Profile D (17%) had the least severe illness, including non-wheezing children with shorter length of stay. Two of these profiles (A and D) were replicated in the Finnish cohort; a third group ('BC') included Finnish children with characteristics of profiles B and/or C in the US population. CONCLUSIONS: Several distinct clinical profiles (phenotypes) were identified by a clustering approach in two multicentre studies of children hospitalised for bronchiolitis. The observed heterogeneity has important implications for future research on the aetiology, management and long-term outcomes of bronchiolitis, such as future risk of childhood asthma. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: Although bronchiolitis is generally considered a single disease, recent studies suggest heterogeneity. We aimed to identify severe bronchiolitis profiles using a clustering approach. METHODS: We analysed data from two prospective, multicentre cohorts of children younger than 2 years hospitalised with bronchiolitis, one in the USA (2007-2010 winter seasons, n=2207) and one in Finland (2008-2010 winter seasons, n=408). Severe bronchiolitis profiles were determined by latent class analysis, classifying children based on clinical factors and viral aetiology. RESULTS: In the US study, four profiles were identified. Profile A (12%) was characterised by history of wheezing and eczema, wheezing at the emergency department (ED) presentation and rhinovirus infection. Profile B (36%) included children with wheezing at the ED presentation, but, in contrast to profile A, most did not have history of wheezing or eczema; this profile had the largest probability of respiratory syncytial virus infection. Profile C (34%) was the most severely ill group, with longer hospital stay and moderate-to-severe retractions. Profile D (17%) had the least severe illness, including non-wheezingchildren with shorter length of stay. Two of these profiles (A and D) were replicated in the Finnish cohort; a third group ('BC') included Finnish children with characteristics of profiles B and/or C in the US population. CONCLUSIONS: Several distinct clinical profiles (phenotypes) were identified by a clustering approach in two multicentre studies of children hospitalised for bronchiolitis. The observed heterogeneity has important implications for future research on the aetiology, management and long-term outcomes of bronchiolitis, such as future risk of childhood asthma. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Shawn L Ralston; Allan S Lieberthal; H Cody Meissner; Brian K Alverson; Jill E Baley; Anne M Gadomski; David W Johnson; Michael J Light; Nizar F Maraqa; Eneida A Mendonca; Kieran J Phelan; Joseph J Zorc; Danette Stanko-Lopp; Mark A Brown; Ian Nathanson; Elizabeth Rosenblum; Stephen Sayles; Sinsi Hernandez-Cancio Journal: Pediatrics Date: 2014-11 Impact factor: 7.124
Authors: Kecia N Carroll; Tebeb Gebretsadik; Marie R Griffin; Pingsheng Wu; William D Dupont; Edward F Mitchel; Rachel Enriquez; Tina V Hartert Journal: Pediatrics Date: 2008-07 Impact factor: 7.124
Authors: Kecia N Carroll; Tebeb Gebretsadik; Patricia Minton; Kimberly Woodward; Zhouwen Liu; E Kathryn Miller; John V Williams; William D Dupont; Tina V Hartert Journal: J Allergy Clin Immunol Date: 2012-02-14 Impact factor: 10.793
Authors: Jonathan M Mansbach; Sunday Clark; Pedro A Piedra; Charles G Macias; Alan R Schroeder; Brian M Pate; Ashley F Sullivan; Janice A Espinola; Carlos A Camargo Journal: J Hosp Med Date: 2015-01-28 Impact factor: 2.960
Authors: Natalie I Mazur; Federico Martinón-Torres; Eugenio Baraldi; Brigitte Fauroux; Anne Greenough; Terho Heikkinen; Paolo Manzoni; Asuncion Mejias; Harish Nair; Nikolaos G Papadopoulos; Fernando P Polack; Octavio Ramilo; Mike Sharland; Renato Stein; Shabir A Madhi; Louis Bont Journal: Lancet Respir Med Date: 2015-09-25 Impact factor: 30.700
Authors: Christopher J Stewart; Jonathan M Mansbach; Pedro A Piedra; Laura Toivonen; Carlos A Camargo; Kohei Hasegawa Journal: Pediatr Allergy Immunol Date: 2019-07-18 Impact factor: 6.377
Authors: Anders Husby; Anu Pasanen; Johannes Waage; Astrid Sevelsted; Hennie Hodemaekers; Riny Janssen; Minna K Karjalainen; Jakob Stokholm; Bo L Chawes; Matti Korppi; Göran Wennergren; Andrea Heinzmann; Louis Bont; Hans Bisgaard; Klaus Bønnelykke Journal: J Allergy Clin Immunol Date: 2017-08-04 Impact factor: 10.793
Authors: Christopher J Stewart; Kohei Hasegawa; Matthew C Wong; Nadim J Ajami; Joseph F Petrosino; Pedro A Piedra; Janice A Espinola; Courtney N Tierney; Carlos A Camargo; Jonathan M Mansbach Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: Carlos E Rodríguez-Martínez; Jose A Castro-Rodriguez; Gustavo Nino; Fabio Midulla Journal: Paediatr Respir Rev Date: 2019-04-12 Impact factor: 2.726
Authors: Orianne Dumas; Kohei Hasegawa; Jonathan M Mansbach; Ashley F Sullivan; Pedro A Piedra; Carlos A Camargo Journal: J Allergy Clin Immunol Date: 2018-09-18 Impact factor: 10.793
Authors: Elie J Mitri; David X Zheng; Vebhav Garg; Cassandra C Crifase; Nicole M Herrera; Janice A Espinola; Kohei Hasegawa; Carlos A Camargo Journal: Pediatr Pulmonol Date: 2021-06-25
Authors: Carlos E Rodriguez-Martinez; Gustavo Nino; Jose A Castro-Rodriguez; Geovanny F Perez; Monica P Sossa-Briceño; Jefferson A Buendia Journal: Pediatr Pulmonol Date: 2020-10-20
Authors: Yoshihiko Raita; Marcos Pérez-Losada; Robert J Freishtat; Brennan Harmon; Jonathan M Mansbach; Pedro A Piedra; Zhaozhong Zhu; Carlos A Camargo; Kohei Hasegawa Journal: Nat Commun Date: 2021-06-14 Impact factor: 17.694